SI1175401T1 - Piperazine derivatives useful as ccr5 antagonists - Google Patents

Piperazine derivatives useful as ccr5 antagonists

Info

Publication number
SI1175401T1
SI1175401T1 SI200030718T SI200030718T SI1175401T1 SI 1175401 T1 SI1175401 T1 SI 1175401T1 SI 200030718 T SI200030718 T SI 200030718T SI 200030718 T SI200030718 T SI 200030718T SI 1175401 T1 SI1175401 T1 SI 1175401T1
Authority
SI
Slovenia
Prior art keywords
derivatives useful
piperazine derivatives
ccr5 antagonists
ccr5
antagonists
Prior art date
Application number
SI200030718T
Other languages
English (en)
Slovenian (sl)
Inventor
Bahige M. Baroudy
John W. Clader
Hubert B. Josien
Stuart W. Mccombie
Brian A. Mckittrick
Michael W. Miller
Bernard R. Neustadt
Anandan Palani
Elizabeth M. Smith
Ruo Steensma
Jayaram R. Tagat
Susan F. Vice
Mark A. Laughlin
Eric Gilbert
Marc A. Labroli
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23179892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1175401(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of SI1175401T1 publication Critical patent/SI1175401T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200030718T 1999-05-04 2000-05-01 Piperazine derivatives useful as ccr5 antagonists SI1175401T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30522699A 1999-05-04 1999-05-04
EP00926486A EP1175401B1 (en) 1999-05-04 2000-05-01 Piperazine derivatives useful as ccr5 antagonists
PCT/US2000/011632 WO2000066558A1 (en) 1999-05-04 2000-05-01 Piperazine derivatives useful as ccr5 antagonists

Publications (1)

Publication Number Publication Date
SI1175401T1 true SI1175401T1 (en) 2005-10-31

Family

ID=23179892

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030718T SI1175401T1 (en) 1999-05-04 2000-05-01 Piperazine derivatives useful as ccr5 antagonists

Country Status (31)

Country Link
EP (2) EP1632479B1 (enExample)
JP (2) JP3722700B2 (enExample)
KR (1) KR100439358B1 (enExample)
AR (5) AR023823A1 (enExample)
AT (2) ATE495154T1 (enExample)
AU (2) AU780888B2 (enExample)
BR (1) BR0010304A (enExample)
CA (1) CA2371583C (enExample)
CH (1) CH1175401H9 (enExample)
CL (1) CL2008002737A1 (enExample)
CO (1) CO5170523A1 (enExample)
CZ (1) CZ20013940A3 (enExample)
DE (2) DE60045528D1 (enExample)
DK (1) DK1175401T3 (enExample)
EG (1) EG24136A (enExample)
ES (1) ES2244437T3 (enExample)
HK (1) HK1039930B (enExample)
HU (1) HUP0202867A3 (enExample)
IL (1) IL145741A0 (enExample)
MY (1) MY128367A (enExample)
NO (1) NO322045B1 (enExample)
PE (1) PE20010150A1 (enExample)
PL (1) PL203116B1 (enExample)
RU (1) RU2299206C9 (enExample)
SA (2) SA06270096B1 (enExample)
SI (1) SI1175401T1 (enExample)
SK (2) SK287418B6 (enExample)
TR (1) TR200103214T2 (enExample)
TW (1) TWI285200B (enExample)
WO (1) WO2000066558A1 (enExample)
ZA (1) ZA200108868B (enExample)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825121B2 (en) * 1999-05-04 2010-11-02 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
CZ20032636A3 (cs) 2001-03-29 2003-12-17 Schering Corporation Látky antagonizující CCR5
DE60230491D1 (de) * 2001-03-29 2009-02-05 Schering Corp Als ccr5-antagonisten verwendbare aryloxim-piperazine
WO2003048153A1 (en) * 2001-11-29 2003-06-12 Schering Corporation Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
EP2311818B1 (en) 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
JP4671091B2 (ja) * 2002-03-18 2011-04-13 東レ・ファインケミカル株式会社 １−置換−２−メチルピペラジンの製造方法
CN100396676C (zh) * 2002-03-29 2008-06-25 先灵公司 作为ccr5拮抗药的哌啶和哌嗪化合物的合成
EP2141143A3 (en) * 2002-03-29 2010-05-05 Schering Corporation Stereoselective alkylation of chiral 2-methyl-4 protected piperazines
US20050245537A1 (en) * 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
JP2003335737A (ja) 2002-05-21 2003-11-28 Central Glass Co Ltd 光学活性（ｒ）−１−（４−トリフルオロメチルフェニル）エチルアミン
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
AU2003289329A1 (en) * 2002-12-13 2004-07-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist binding to strong binding site of chemokine receptor
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1619193A4 (en) 2003-04-18 2010-08-11 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
EP1616862A4 (en) * 2003-04-18 2008-07-16 Ono Pharmaceutical Co HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0313661D0 (en) * 2003-06-13 2003-07-16 Avecia Ltd Process
EP1633737A1 (en) * 2003-06-13 2006-03-15 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists
US7345042B2 (en) 2003-06-30 2008-03-18 Schering Corporation MCH antagonists for the treatment of obesity
EP1687295B1 (en) 2003-11-03 2011-08-17 Schering Corporation Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CA2554465A1 (en) 2004-02-05 2005-08-25 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
EP1716156A2 (en) * 2004-02-10 2006-11-02 F.Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
BRPI0508140B1 (pt) 2004-03-05 2015-03-17 Nissan Chemical Ind Ltd Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
AU2005234596B8 (en) 2004-04-13 2011-06-16 Incyte Holdings Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
PT1761542E (pt) 2004-06-09 2008-03-26 Hoffmann La Roche Derivados de octa-hidro-pirrolo[3,4-c) pirrole e o seu uso com agentes antivirais
GB0417804D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CA2594109A1 (en) * 2005-01-06 2006-07-13 Schering Corporation Preparation of pharmaceutical salts of piperazine compounds
ATE523506T1 (de) 2005-02-16 2011-09-15 Schering Corp Amingebundene pyridyl- und phenylsubstituierte piperazin-piperidine mit cxcr3-antagonistischer aktivität
MX2007010068A (es) * 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
WO2006088919A2 (en) * 2005-02-16 2006-08-24 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
US7417045B2 (en) 2005-02-16 2008-08-26 Schering Corporation Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
CN101142209A (zh) * 2005-02-16 2008-03-12 先灵公司 具有cxcr3拮抗剂活性的吡嗪基取代的哌嗪-哌啶
PE20061012A1 (es) * 2005-02-23 2006-10-03 Schering Corp Derivados piperidinil piperazina como inhibidores de receptores quiomicina
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2006129679A1 (ja) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
PT1893603E (pt) 2005-06-02 2009-11-24 Hoffmann La Roche Derivados de piperidin-4-il-amida e a sua utilização como antagonistas do receptor de sst do subtipo 5
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
JP5217438B2 (ja) 2005-11-18 2013-06-19 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
WO2007064620A2 (en) * 2005-11-30 2007-06-07 Schering Corporation Compositions comprising a combination of ccr5 and cxcr4 antagonists
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
NZ569814A (en) 2006-01-18 2011-10-28 Schering Corp Cannibinoid receptor modulators
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP2013211B1 (en) 2006-04-21 2012-03-14 Novartis AG Purine derivatives for use as adenosin a2a receptor agonists
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
PT2057125E (pt) 2006-08-16 2011-05-31 Hoffmann La Roche Inibidores n?o nucle?sidos de transcriptase inversa
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
KR101475091B1 (ko) 2006-12-13 2014-12-22 에프. 호프만-라 로슈 아게 비뉴클레오시드 역전사 효소 억제제로서 2-(피페리딘-4-일)-4-페녹시- 또는 페닐아미노-피리미딘 유도체
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
CA2673803A1 (en) 2007-01-10 2008-07-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
JP5550352B2 (ja) 2007-03-15 2014-07-16 ノバルティス アーゲー 有機化合物およびその使用
CA2682639A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
ATE499363T1 (de) 2007-05-07 2011-03-15 Novartis Ag Organische verbindungen
EP2155689B1 (en) 2007-05-31 2015-07-08 Boehringer Ingelheim International GmbH Ccr2 receptor antagonists and uses thereof
RU2010116821A (ru) * 2007-10-01 2011-11-10 Ф.Хоффманн-Ля Аг (Ch) N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr
NZ585789A (en) 2007-12-10 2012-03-30 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
AU2009220462A1 (en) * 2008-02-29 2009-09-11 Merck Sharp & Dohme Corp. CCR5 antagonists as prophylactics for preventing HIV infection and methods of inhibiting transmission of same
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2009128947A1 (en) * 2008-04-17 2009-10-22 Concert Pharmaceuticals, Inc. Piperazine derivatives
MX2010013675A (es) 2008-06-10 2011-02-15 Novartis Ag Derivados de pirazina como bloqueadores del canal de sodio epitelial.
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
PE20120061A1 (es) 2008-12-19 2012-02-19 Boehringer Ingelheim Int Derivados de pirimidina como antagonistas del receptor ccr2
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
WO2011073154A1 (en) 2009-12-17 2011-06-23 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists and uses thereof
JP5658272B2 (ja) * 2009-12-17 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２の新規アンタゴニスト及びこれらの使用
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5646736B2 (ja) 2010-05-12 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
AU2011278279C1 (en) 2010-07-14 2014-11-27 Novartis Ag IP receptor agonist heterocyclic compounds
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
US20150005311A1 (en) 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105066A1 (en) 2012-01-13 2013-07-18 Novartis Ag Salts of an ip receptor agonist
US20140378463A1 (en) 2012-01-13 2014-12-25 Novartis Ag IP receptor agonist heterocyclic compounds
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
EP2956455B1 (en) 2013-02-13 2017-05-17 Novartis AG Ip receptor agonist heterocyclic compounds
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
EP3134396B1 (en) 2014-04-24 2019-09-18 Novartis AG Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
WO2016016822A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
WO2016028971A1 (en) * 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
EP3317270B1 (en) 2015-07-02 2020-05-13 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
WO1999004794A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
JP3344997B2 (ja) * 1998-06-30 2002-11-18 シェーリング コーポレイション ムスカリン性アンタゴニスト

Also Published As

Publication number Publication date
EP1632479B1 (en) 2011-01-12
AR057873A2 (es) 2007-12-26
MY128367A (en) 2007-01-31
HUP0202867A3 (en) 2004-01-28
EP1175401A1 (en) 2002-01-30
EP1175401B1 (en) 2005-07-20
AR057107A2 (es) 2007-11-14
NO322045B1 (no) 2006-08-07
HUP0202867A2 (hu) 2003-01-28
AU780888B2 (en) 2005-04-21
EP1632479A2 (en) 2006-03-08
JP2002543185A (ja) 2002-12-17
AR057106A2 (es) 2007-11-14
CH1175401H1 (de) 2007-02-15
PL203116B1 (pl) 2009-08-31
BR0010304A (pt) 2002-02-13
DE60045528D1 (de) 2011-02-24
KR20020019907A (ko) 2002-03-13
TR200103214T2 (tr) 2002-03-21
ES2244437T3 (es) 2005-12-16
CA2371583A1 (en) 2000-11-09
SA00210271B1 (ar) 2006-07-30
SK286641B6 (sk) 2009-03-05
AU2005202357B2 (en) 2009-04-02
PL351388A1 (en) 2003-04-07
AU2005202357A1 (en) 2005-06-23
NO20015366L (no) 2002-01-03
ZA200108868B (en) 2003-01-27
HK1039930B (en) 2005-12-09
DE60021370D1 (de) 2005-08-25
DE60021370T2 (de) 2006-04-27
RU2299206C9 (ru) 2007-11-20
HK1039930A1 (en) 2002-05-17
IL145741A0 (en) 2002-07-25
CA2371583C (en) 2005-09-13
KR100439358B1 (ko) 2004-07-07
TWI285200B (en) 2007-08-11
CL2008002737A1 (es) 2009-01-16
WO2000066558A1 (en) 2000-11-09
SK15692001A3 (sk) 2002-07-02
AU4500900A (en) 2000-11-17
ATE299865T1 (de) 2005-08-15
SK287418B6 (sk) 2010-09-07
DE60021370C5 (de) 2007-11-08
AR023823A1 (es) 2002-09-04
EG24136A (en) 2008-08-06
DK1175401T3 (da) 2005-11-14
PE20010150A1 (es) 2001-02-09
EP1632479A3 (en) 2007-05-09
CZ20013940A3 (cs) 2002-04-17
CO5170523A1 (es) 2002-06-27
NO20015366D0 (no) 2001-11-02
ATE495154T1 (de) 2011-01-15
JP3722700B2 (ja) 2005-11-30
RU2299206C2 (ru) 2007-05-20
JP2006052225A (ja) 2006-02-23
CH1175401H9 (de) 2007-03-30
AR057786A2 (es) 2007-12-19
SA06270096B1 (ar) 2009-02-25

Similar Documents

Publication Publication Date Title
EG24136A (en) Piperazine derivatives useful as ccr5 antagonists
IL145742A0 (en) Piperidine derivatives useful as ccr5 antagonists
PL362900A1 (en) Piperazine derivatives as 5-ht1b antagonists
SI1218359T1 (en) Piperazine compounds as tachykinins antagonists
PL356034A1 (en) Cyclic amine compounds as ccr5 antagonists
EP1206262A4 (en) Y NEUROPEPTID ANTAGONISTS: SPIROISOQUINOLINONE DERIVATIVES
IL151923A0 (en) Novel piperazine derivatives
IL160060A0 (en) Piperidine derivatives useful as ccr5 antagonists
AU2001233685A1 (en) Piperidine and piperazine derivatives which function as 5-HT2A receptor antagonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
IL146629A0 (en) Indolylpiperidine derivatives as antihistaminic and antiallergic agents
IL144720A0 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists
IL148623A0 (en) Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists
AU2541000A (en) Beta-phenylalanine derivatives as integrin antagonists
IL181191A0 (en) Piperazine and piperidine derivatives and their use as chemokine receptor antagonists
HUP0203855A3 (en) Substituted piperazine derivatives as mtp inhibitors
GB0026578D0 (en) Heterocyclic derivatives useful as pharmaceutical agents
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
SI1216239T1 (en) Piperazine derivatives as 5-ht1b antagonists
SI1155013T1 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists
HK1061689A (en) Piperazine derivatives as tachykinin antagonists
AU2002251242A1 (en) Piperazine derivatives as tachykinin antagonists
AU2002346986A1 (en) N-aroyl piperazine derivatives as orexin receptor antagonists